Genovis rights issue oversubscribed

The issue was subscribed for SEK 28,632,631, which it was oversubscribed by 21
%.
Of the total issue volume of 5,260,252 shares, 88 % were subscribed for with
preferential rights. The rights issue raised about SEK 23.7 million before issue
expenses for Genovis. Statements of account will be sent on December 19, 2013,
to allot shares subscribed for without preferential rights.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00